The VA has been steadily increasing its capacity to whole-genome sequence enrollees, and may now sequence as many as 30,000 individuals over the next two years.
The deal replaces an existing cancer testing contract to include PGDx's CancerSelect 125 test for pan-cancer tumor profiling.
VA patients will now have access to Polymedco's colorectal cancer screening products, including the Epigenomics Epi proColon.
The contract provides coverage of ConfirmMDx testing at the Medicare rate for veterans within the VA health system.
The company will apply artificial intelligence to a large clinical and genomic dataset from VA records in order to support personalized clinical decision making.
The new partnership will make data from more than 9 million anonymized veterans' medical records available for research.
The company has been working with the VA since 2013, when it it received a contract to provide sequencing and data analysis for enrollees in the Million Veteran Program.
Announced this month, the project brings together CPTAC, the VA, and DoD, and has as its initial goal the proteogenomic analysis of 8,000 lung cancer patients.
With NIH funds, organizations will build the 1 million volunteer cohort, while FDA's draft guidances will inform regulation of genetic tests critical for precision medicine.
The deal, which will help develop personalized cancer treatments for veterans, marks the latest in a series of personalized medicine alliances for IBM.
The New York Times Magazine examines gender discrimination at the Salk Institute.
Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.
A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.
In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.